Quanticate, a data-focused global clinical research organization (CRO), chose Comprehend Clinical™to integrate into its future research tools as a key part of its strategy to expand its offerings to meet growing sponsor demand for real-time communications and comprehensive clinical data analytics.
“We are excited to be able to provide our sponsor customers a more user-friendly, cost effective approach that overcomes the limitations of analytics and visualization tools that are costly and cumbersome to implement and integrate with other systems. Our approach will help our customers get to the data they need to answer critical questions,” said Daniel Chapple, chief commercial officer at Quanticate. “Our selection of Comprehend Systems is a fundamental step in our vision to provide our customers with centralized clinical data services that helps them resolve this data access challenge.”
After Quanticate conducted a thorough evaluation of a range of data analytics vendors, Comprehend Clinical was chosen for its easy-to-use web-based platform and ability to seamlessly integrate into existing clinical systems. The Quanticate team also valued how the system allows researchers to easily find answers to their problems and dig into key data with no additional programming or complicated spreadsheets.
“During our evaluation process of visualization and analytics software, it became clear that Comprehend Clinical’s competitive advantage is its ability to pull data from any source and deliver it in a way that makes sense to researchers,” said Michael Whitworth, vice president of centralized clinical data sciences at Quanticate. “Comprehend Clinical will enable our sponsors to not only drill down and solve unique, specific problems in real time, but also provide a higher level view of data to tackle broader operational challenges.”
“As a leading CRO, Quanticate clearly understands the regulatory, clinical and financial pressures sponsors are under and is aggressively implementing the technologies and services that solve the industry’s biggest pain points,” said Rick Morrison, CEO and founder of Comprehend Systems. “Given our shared commitment to improving the way clinical research is conducted, Quanticate’s strategy to integrate our solution makes perfect sense, and we look forward to successes with joint customers in the months ahead.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.